Chong Kun Dang Pharmaceutical Corp. (185750.KS) Stock

185750.KS logo

Chong Kun Dang Pharmaceutical Corp.

185750.KSSouth Korea
Healthcare

Company profile

Chong Kun Dang Pharmaceutical reported revenue of 1.69 trillion KRW for fiscal year 2025, up 6.7% from fiscal year 2024, and net income of 77.51 billion KRW. That is a net profit margin of 4.6% for fiscal year 2025. In Q1 2026 (the quarter ended March 31, 2026) revenue was 447.77 billion KRW, up 11.7% from a year before. South Korea was its largest region in fiscal year 2025, with 96% of revenue. In Q1 2026 it reported net income of 12.82 billion KRW, against net income of 11.78 billion KRW a year earlier. Our analysis of its filings shows revenue growing from 1.67 trillion KRW in fiscal year 2023 to 1.69 trillion KRW in fiscal year 2025, 0.7% a year on average. Chong Kun Dang Pharmaceutical reports about 2,170 full-time employees.

What stands out

  • Revenue in fiscal year 2025 was the highest of the last 5 fiscal years.

Figures from company filings; latest fiscal year ended December 31, 2025.

About Chong Kun Dang Pharmaceutical Corp.

Chong Kun Dang Pharmaceutical Corp. manufactures, markets, and sells medicines in South Korea and internationally. It offers prescription drugs for anti-hypertension, anti-hyperlipidaemia, and anti-diabetics, as well as immunosuppressants; over-the-counter medicines; and consumer health products, such as insecticides and hair dye products, as well as health supplements. The company was founded in 1941 and is headquartered in Seoul, South Korea.

Largest shareholders

  • Chong Kun Dang Holdings Corp.26.70%
  • Jang-Han Lee9.555 %9.55%
  • Kopernik Global Investors LLC8.38%
  • National Pension Service of Korea6.34%
  • Kochon Foundation5.12%

Share of the company, as of September 25, 2026

Leadership

  • Young-Joo Kim — President, CEO & Chairman
  • GyuWoong Lee — Director & Head of Marketing
  • Woo Lee — Director & HR Manager, 49
  • Yu-kyung Kwon — Director & Head of the Development Center

How much revenue does Chong Kun Dang Pharmaceutical make?

Chong Kun Dang Pharmaceutical reported 1.69 trillion KRW in revenue for fiscal year 2025, up 6.7% from 1.59 trillion KRW in fiscal year 2024. In Q1 2026 revenue was 447.77 billion KRW.

Where does Chong Kun Dang Pharmaceutical make most of its revenue?

South Korea: 96% of revenue by region in fiscal year 2025, followed by Japan (3%).

What companies are similar to Chong Kun Dang Pharmaceutical?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include GC Biopharma Corp. (006280.KS), Daewoong Pharmaceutical Co., Ltd (069620.KS), HK inno.N Corporation (195940.KQ), Boryung Corporation (003850.KS).

How has Chong Kun Dang Pharmaceutical's revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2021, 1.34 trillion KRW; FY2022, 1.49 trillion KRW; FY2023, 1.67 trillion KRW; FY2024, 1.59 trillion KRW; FY2025, 1.69 trillion KRW.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Employees2,170
HeadquartersSeoul, South Korea
ExchangeKSE
TimezoneAsia/Seoul (KST)

Contact & Links

Address
Chong Kun Dang Building, Seoul
Phone
82 2 2194 0300
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Chong Kun Dang Pharmaceutical Corp. (185750.KS)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/185750.KS

LinkedInLinkedInXXYouTubeYouTube